Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

32.17
+0.40001.26%
Post-market: 32.170.00000.00%17:49 EST
Volume:985.32K
Turnover:31.66M
Market Cap:2.82B
PE:-17.65
High:33.00
Open:32.68
Low:31.86
Close:31.77
52wk High:39.28
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:1.30
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8227
EPS(LYR):-3.3605
ROE:-14.15%
ROA:-10.77%
PB:2.58
PE(LYR):-9.57

Loading ...

IDEAYA Biosciences Joins Virtual Oncology Leadership Summit and Hosts Investor Fireside Chat

Reuters
·
Feb 02

BRIEF-IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
Jan 30

IDEAYA Biosciences Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Jan 30

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 30

IDEAYA Biosciences Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 21

RBC Raises Price Target on IDEAYA Biosciences to $45 From $41, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 21

IDEAYA Biosciences (IDYA) Receives a Buy from Citi

TIPRANKS
·
Jan 14

IDEAYA Biosciences Announces 2026 Pipeline Advancements and Reports $1.1 Billion Cash Position

Reuters
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Jan 12

Ideaya Biosciences provides business update for 2026

TIPRANKS
·
Jan 12

IDEAYA Biosciences Releases Updated Corporate Presentation

Reuters
·
Jan 12

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 12

IDEAYA Biosciences Coverage Assumed by UBS at Buy

Dow Jones
·
Jan 08

IDEAYA Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 06

IDEAYA Biosciences Presents at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

IDEAYA Biosciences (IDYA): Valuation Check After Key Phase 2/3 Milestone for Darovasertib in Uveal Melanoma

Simply Wall St.
·
Dec 26, 2025

IDEAYA Biosciences (IDYA): Valuation Check After Key Darovasertib Trial Milestone and Pipeline Progress

Simply Wall St.
·
Dec 16, 2025

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live
·
Dec 11, 2025

IDEAYA Biosciences Completes Enrollment in Pivotal Phase 2/3 Trial of Darovasertib and Crizotinib for Metastatic Uveal Melanoma

Reuters
·
Dec 11, 2025

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (Optimum-02) of Darovasertib in Combination With Crizotinib in First-Line Hla*a2-Negative Metastatic Uveal Melanoma

THOMSON REUTERS
·
Dec 11, 2025